Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

Fig. 3

Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.05 for the Kshirsagar et al. risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us